4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Cullinan Therapeutics, Inc. (CGEM) operates in the Biotechnology industry and is headquartered in Cambridge, United States with about 109 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, CGEM reported $0M in revenue and ($220M) in net income.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($242M) | ($197M) | ($191M) | ($132M) | — |
| Net Income | ($220M) | ($167M) | ($153M) | $111M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($54M) | ($55M) | ($56M) | ($76M) | ($55M) | — |
| Net Income | ($50M) | ($51M) | ($51M) | ($70M) | ($48M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $448M | $622M | $484M | $561M | — |
| Total Liabilities | $40M | $32M | $30M | $26M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CGEM viewer.
About TickerBase · Data methodology & sources